Use of Dienogest or Gonadotropin Releasing Hormone Agonist with Add back Hormone Therapy in Longterm Endometriosis Medical Management
نویسندگان
چکیده
منابع مشابه
Sequential Management with Gonadotropin-Releasing Hormone Agonist and Dienogest of Endometriosis-Associated Uterine Myoma and Adenomyosis
Uterine leiomyoma and adenomyosis represent the most common benign tumors of the female reproductive system (Levy, 2008; Parker, 2007; Sankaran & Manyonda, 2008). These tumors are estrogen dependent, develop during the reproductive period, and are suppressed with menopause. Traditional treatments for myomas and adenomyosis have been various types of surgical techniques. Medical management of th...
متن کاملHormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
OBJECTIVE To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agonists for endometriosis. Gonadotropin-releasing hormone agonists are associated with deleterious effects on bone. Hormonal add-back may mitigate these effects. ...
متن کاملEffects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis
OBJECTIVE To compare the efficacy of different add-back regimens on hypoestrogenic symptoms during postoperative gonadotropin-releasing hormone (GnRH) agonist treatment in endometriosis patients. METHODS This prospective cohort study included reproductive-aged women who underwent conservative laparoscopic surgery for ovarian endometriosis and received add-back therapy during a 6-month course ...
متن کاملgonadotropin-releasing hormone agonist therapy and obesity in girls
results from 110 subjects with cpp, 46 girls (41.8%) were considered as intervention and 64 (58.2%) as control groups. the mean age at initial visit was 7.46 ± 1.03 years. the bmi standard deviation scores in both groups was not significantly different at sixth and 12th months of treatment compared with baseline (p = 0.257 and p = 0.839, respectively). the prevalence of obesity was not signific...
متن کاملGonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
BACKGROUND Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. A concern about these drugs is obesity. OBJECTIVES This study aimed to investigate the effect of gonadotropin-releasing hormone agonists (GnRHa) therapy on body mass index (BMI) in girls with central precocious puberty (CPP). PATIENTS ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Open Access Journal of Gynecology
سال: 2018
ISSN: 2474-9230
DOI: 10.23880/oajg-16000151